Pembrolizumab (Keytruda) for the first-line treatment of advanced renal cell cancer with a favorable or intermediate prognosis
In 2020, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of pembrolizumab in combination with axitinib compared to the standard treatments for advanced renal cell carcinoma with a favorable or intermediate in adults who have not yet had any treatment.
The manufacturer provided one study for this assessment. It was possible to analyze the data of 753 patients from this study. 376 of them were given pembrolizumab and axitinib, and 377 received sunitinib.
This is what was found: